Effect of progestogen and progestogen type on hemostasis measures in postmenopausal women: the Postmenopausal Estrogen/Progestin Intervention (PEPI) Study

Menopause. 2008 Nov-Dec;15(6):1145-50. doi: 10.1097/gme.0b013e3181775eca.

Authors

Nicholas L Smith¹, Jennifer R Wiley, Claudine Legault, Kenneth M Rice, Susan R Heckbert, Bruce M Psaty, Russell P Tracy, Mary Cushman

Affiliation

¹ Department of Epidemiology, University of Washington, and Seattle Epidemiologic Research and Information Center of the Department of Veterans Affairs Office of Research and Development, Seattle, WA

PMID: 19186375
DOI: 10.1097/gme.0b013e3181775eca

No abstract available

Publication types

Multicenter Study
Randomized Controlled Trial

MeSH terms

Antigens / drug effects
Estrogen Replacement Therapy / adverse effects*
Estrogens, Conjugated (USP) / therapeutic use
Factor VII / drug effects
Female
Follow-Up Studies
Hemostasis / drug effects*
Humans
Medroxyprogesterone Acetate / adverse effects*
Middle Aged
Plasminogen Activator Inhibitor 1 / metabolism
Progesterone / adverse effects*
Prospective Studies
Protein C / drug effects

Substances

Antigens
Estrogens, Conjugated (USP)
Plasminogen Activator Inhibitor 1
Protein C
factor VII clotting antigen
Progesterone
Factor VII
Medroxyprogesterone Acetate